Bronchoscopic Lung Ablation of Small Thoracic Tumors: the Blastt Registry
Sponsored by M.D. Anderson Cancer Center
About this study
To aggregate, integrate, and analyze data facilitating the study of MD Anderson patients with a known diagnosis of lung cancer or metastases to the lungs who undergo robotic assisted bronchoscopic ablation of peripheral tumors.
A. To aggregate, integrate, and analyze data facilitating the study of MD Anderson participants with a known diagnosis of lung cancer or metastases to the lungs who undergo robotic assisted bronchoscopic ablation of peripheral tumors. B. To assess the intra-operative, peri-operative, and long-term safety outcomes of robotic assisted bronchoscopic ablation of peripheral lung tumors. C. To evaluate different oncologic outcomes including local tumor progression (LTP) by RECIST criteria, local tumor progression free survival (LTPFS), progression free-survival (PFS), disease (cancer) specific survival (DSS), and overall survival (OS). D. To provide a deeper understanding of the evolution of radiographic findings of bronchoscopically ablated lung tumors over time. E. To evaluate tumor and pa…
Where this study is enrolling
- I'm interested
MD Anderson Cancer Center
Houston, Texas
Who can participate
Inclusion criteria
- ✓Patients with peripheral lung tumors (primary or metastatic) that have been or will be ablated via robotic bronchoscopy.
Exclusion criteria
- ✕Patients with planned bronchoscopic ablations of peripheral lung tumors that were aborted for technical reasons (ablation was not completed).
Only the research team can confirm whether you qualify. The intake questionnaire is the best way to find out.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.